Shunji Haruta
Hoofd Techniek/Wetenschap/O&O bij SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
Actieve functies van Shunji Haruta
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. | Hoofd Techniek/Wetenschap/O&O | 01-01-2011 | - |
| SATSUMA PHARMACEUTICALS, INC. | Directeur/Bestuurslid | 08-06-2023 | - |
Loopbaan van Shunji Haruta
Statistieken
Internationaal
| Japan | 2 |
| Verenigde Staten | 2 |
Operationeel
| Chief Tech/Sci/R&D Officer | 1 |
| Director/Board Member | 1 |
Sectoraal
| Commercial Services | 2 |
| Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. | Commercial Services |
| Bedrijven in privébezit | 1 |
|---|---|
Satsuma Pharmaceuticals, Inc.
 Satsuma Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraines. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in Durham, NC. | Health Technology |
- Beurs
- Insiders
- Shunji Haruta
- Ervaring
